Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS

Markus Otto, Robert Bowser, Martin Turner, James Berry, Johannes Brettschneider, James Connor, Jlia Costa, Merit Cudkowicz, Jonathan Glass, Olaf Jahn, Stefan Lehnert, Andrea Malaspina, Lucilla Parnetti, Axel Petzold, Pamela Shaw, Alexander Sherman, Petra Steinacker, Sigurd Sßmuth, Charlotte Teunissen, Hayrettin Tumani & 2 others Anna Wuolikainen, Albert Ludolph

Research output: Contribution to journalReview article

61 Citations (Scopus)

Abstract

Despite major advances in deciphering the neuropathological hallmarks of amyotrophic lateral sclerosis (ALS), validated neurochemical biomarkers for monitoring disease activity, earlier diagnosis, defining prognosis and unlocking key pathophysiological pathways are lacking. Although several candidate biomarkers exist, translation into clinical application is hindered by small sample numbers, especially longitudinal, for independent verification. This review considers the potential routes to the discovery of neurochemical markers in ALS, and provides a consensus statement on standard operating procedures that will facilitate multicenter collaboration, validation and ultimately clinical translation.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalAmyotrophic Lateral Sclerosis
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

Amyotrophic Lateral Sclerosis
Biomarkers
Early Diagnosis

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Otto, Markus ; Bowser, Robert ; Turner, Martin ; Berry, James ; Brettschneider, Johannes ; Connor, James ; Costa, Jlia ; Cudkowicz, Merit ; Glass, Jonathan ; Jahn, Olaf ; Lehnert, Stefan ; Malaspina, Andrea ; Parnetti, Lucilla ; Petzold, Axel ; Shaw, Pamela ; Sherman, Alexander ; Steinacker, Petra ; Sßmuth, Sigurd ; Teunissen, Charlotte ; Tumani, Hayrettin ; Wuolikainen, Anna ; Ludolph, Albert. / Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. In: Amyotrophic Lateral Sclerosis. 2012 ; Vol. 13, No. 1. pp. 1-10.
@article{f783f2cb9aa64a2fbc3911fdeb953b0b,
title = "Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS",
abstract = "Despite major advances in deciphering the neuropathological hallmarks of amyotrophic lateral sclerosis (ALS), validated neurochemical biomarkers for monitoring disease activity, earlier diagnosis, defining prognosis and unlocking key pathophysiological pathways are lacking. Although several candidate biomarkers exist, translation into clinical application is hindered by small sample numbers, especially longitudinal, for independent verification. This review considers the potential routes to the discovery of neurochemical markers in ALS, and provides a consensus statement on standard operating procedures that will facilitate multicenter collaboration, validation and ultimately clinical translation.",
author = "Markus Otto and Robert Bowser and Martin Turner and James Berry and Johannes Brettschneider and James Connor and Jlia Costa and Merit Cudkowicz and Jonathan Glass and Olaf Jahn and Stefan Lehnert and Andrea Malaspina and Lucilla Parnetti and Axel Petzold and Pamela Shaw and Alexander Sherman and Petra Steinacker and Sigurd S{\ss}muth and Charlotte Teunissen and Hayrettin Tumani and Anna Wuolikainen and Albert Ludolph",
year = "2012",
month = "1",
day = "1",
doi = "10.3109/17482968.2011.627589",
language = "English (US)",
volume = "13",
pages = "1--10",
journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",
issn = "2167-8421",
publisher = "Informa Healthcare",
number = "1",

}

Otto, M, Bowser, R, Turner, M, Berry, J, Brettschneider, J, Connor, J, Costa, J, Cudkowicz, M, Glass, J, Jahn, O, Lehnert, S, Malaspina, A, Parnetti, L, Petzold, A, Shaw, P, Sherman, A, Steinacker, P, Sßmuth, S, Teunissen, C, Tumani, H, Wuolikainen, A & Ludolph, A 2012, 'Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS', Amyotrophic Lateral Sclerosis, vol. 13, no. 1, pp. 1-10. https://doi.org/10.3109/17482968.2011.627589

Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. / Otto, Markus; Bowser, Robert; Turner, Martin; Berry, James; Brettschneider, Johannes; Connor, James; Costa, Jlia; Cudkowicz, Merit; Glass, Jonathan; Jahn, Olaf; Lehnert, Stefan; Malaspina, Andrea; Parnetti, Lucilla; Petzold, Axel; Shaw, Pamela; Sherman, Alexander; Steinacker, Petra; Sßmuth, Sigurd; Teunissen, Charlotte; Tumani, Hayrettin; Wuolikainen, Anna; Ludolph, Albert.

In: Amyotrophic Lateral Sclerosis, Vol. 13, No. 1, 01.01.2012, p. 1-10.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS

AU - Otto, Markus

AU - Bowser, Robert

AU - Turner, Martin

AU - Berry, James

AU - Brettschneider, Johannes

AU - Connor, James

AU - Costa, Jlia

AU - Cudkowicz, Merit

AU - Glass, Jonathan

AU - Jahn, Olaf

AU - Lehnert, Stefan

AU - Malaspina, Andrea

AU - Parnetti, Lucilla

AU - Petzold, Axel

AU - Shaw, Pamela

AU - Sherman, Alexander

AU - Steinacker, Petra

AU - Sßmuth, Sigurd

AU - Teunissen, Charlotte

AU - Tumani, Hayrettin

AU - Wuolikainen, Anna

AU - Ludolph, Albert

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Despite major advances in deciphering the neuropathological hallmarks of amyotrophic lateral sclerosis (ALS), validated neurochemical biomarkers for monitoring disease activity, earlier diagnosis, defining prognosis and unlocking key pathophysiological pathways are lacking. Although several candidate biomarkers exist, translation into clinical application is hindered by small sample numbers, especially longitudinal, for independent verification. This review considers the potential routes to the discovery of neurochemical markers in ALS, and provides a consensus statement on standard operating procedures that will facilitate multicenter collaboration, validation and ultimately clinical translation.

AB - Despite major advances in deciphering the neuropathological hallmarks of amyotrophic lateral sclerosis (ALS), validated neurochemical biomarkers for monitoring disease activity, earlier diagnosis, defining prognosis and unlocking key pathophysiological pathways are lacking. Although several candidate biomarkers exist, translation into clinical application is hindered by small sample numbers, especially longitudinal, for independent verification. This review considers the potential routes to the discovery of neurochemical markers in ALS, and provides a consensus statement on standard operating procedures that will facilitate multicenter collaboration, validation and ultimately clinical translation.

UR - http://www.scopus.com/inward/record.url?scp=84855410186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855410186&partnerID=8YFLogxK

U2 - 10.3109/17482968.2011.627589

DO - 10.3109/17482968.2011.627589

M3 - Review article

VL - 13

SP - 1

EP - 10

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

SN - 2167-8421

IS - 1

ER -